Abstract: The invention relates to exsulins or insulin mimetic amino acid sequences with a molecular weight of up to 55,000 daltons and with 1 to 50 basic units of following Formula (1): [?] L,V,I,A]-X1—X2-[L,V,I,A]-[D,E]-[N,Q,M]-X3—[C,H]—X4 [?], whereby; [L,V,I,A], [D,E], [N,Q,M], [C,H] and X1 to 4 represent peptidically linked amino acids; [L,V,I,A] represents leucine (L), valine (V), isoleucine (I) or alanine (A); [D,E] represents asparaginic acid (D) or glutamic acid (E); [N,Q,M] represents asparagine (N), glutamine (Q) or methionine (M); [C,H] represents cysteine (C) or histidine (H); both groups [L,V,I,A] in a basic unit can be identical or different; X1, X2, X3 and X4 represent any type of amino acid and the four amino acids X1 to 4 in a basic unit can be identical or different.

Abstract: The invention relates to bioactive ribonucleo polypeptides (RNP) containing copper, zinc or calcium. These are non-mitogenic morphogens for blood vessels of a defined primary structure for intercellular communication with genetic information. Zn/Ca/Cu-RNP can enzymatically hydrolyse nucleinic acids in a regulated manner (regulated nuclease activity) and be modulated and regulated via Zn/Ca/Cu-metal ion contents as "molecular switches" in mutual bioactivity. The compounds selectively stimulate the directional growth of the morphogenesis of blood vessels in vivo and in vitro and lead to neovascularisation of tissues. The invention further relates to a method of producing and obtaining the RNP as well as its utilisation, and medicines.